vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2018-15-4-493-502vestim-463Research ArticleОБЗОРЫREVIEWSИспользование иммунобиологических препаратов в терапии ревматоидного артритUse of immunobiological drugs in the treatment of rheumatoid arthritisВолковаМ. В.VolkavaM. V.

канд. мед. наук, вед. науч. сотрудник

Ph. D. (Med.), Leading researcher

margovolkova@gmail.comКундерЕ. В.KunderA. V.

д-р мед. наук, профессор

D. Sc. (Med.), Professor

elsid7@mail.ruБелорусская медицинская академия последипломного образования, МинскBelarusian Medical Academy of Postgraduate Education, Minsk201814012019154493502Copyright © Волкова М.В., Кундер Е.В., 20192019Волкова М.В., Кундер Е.В.Volkava M.V., Kunder A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/463

В данной статье рассматриваются вопросы оптимизации терапии ревматоидного артрита биологическими базисными противовоспалительными препаратами на основании определенных клинико-иммунологических предикторов. Приводится описание наиболее значимых предикторов, таких как индекс массы тела, курение, активность болезни, сопутствующая терапия и прогнозирование эффективности того или иного биологического препарата при наличии антител. Также приводятся данные о возможности прогнозирования ответа на определенный вид биологической терапии исходя из клинического варианта ревматоидного артрита.

In this article, we discuss the modern approaches to optimize rheumatoid arthritis therapy with biological antiinflammatory drugs using specific predictors. We describe the most important predictors such as body mass index, smoking, disease activity, concomitant therapy, and the presence of antibodies in predicting the effectiveness of biologicals. Also, we provide data on the ability to predict the response to a certain type of biological therapy on the basis of clinical variants of rheumatoid arthritis.

ревматоидный артритлечениебиологические препаратыклинические вариантыrrheumatoid arthritistreatmentbiological drugsclinical variantsReferencesTreating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force [Guideline] / J. S. Smolen [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75, N 1. – P. 3–15. https://doi.org/10.1136/annrheumdis-2015-207524Smolen J. S., Breedveld F. C., Burmester G. R., Bykerk V., Dougados M., Emery P. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, vol. 75, no. 1, pp. 3–15. https://doi.org/10.1136/annrheumdis-2015-207524Kiely, P. D. W. Biologic efficacy optimization – a step towards personalized medicine/ P. D. W. Kiely // Rheumatology. – 2015. – Vol. 55, N 5. – P. 780–788. https://doi.org/10.1093/rheumatology/kev356Kiely P. D. W. Biologic efficacy optimization – a step towards personalized medicine. Rheumatology, 2015, vol. 55, no. 5, pp. 780–788. https://doi.org/10.1093/rheumatology/kev356The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review / J. T. Joensuu [et al.] // PLoS ONE. – 2015. – Vol. 10, N 3. – P. e0119683. https://doi.org/10.1371/journal.pone.0119683Joensuu J. T., Huoponen S., Aaltonen K. J., Konttinen Y. T., Nordström D., Blom M. The cost-effectiveness of bio logics for the treatment of rheumatoid arthritis: a systematic review. PLoS ONE, 2015, vol. 10, no. 3, pp. e0119683. https://doi.org/10.1371/journal.pone.0119683Firestein, G. S. The disease formerly known as rheumatoid arthritis / G. S. Firestein // Arthritis Res. Ther. – 2014. – Vol. 16, N 3. – Art. 114. https://doi.org/10.1186/ar4593Firestein G. S. The disease formerly known as rheumatoid arthritis. Arthritis Research & Therapy, 2014, vol. 16, no. 3, art. 114. https://doi.org/10.1186/ar4593Клинический полиморфизм ревматоидного артрита в белорусской популяции пациентов / Е. В. Кундер [и др.] // Медицина. – 2017. – № 2. – С. 63–70.Kunder E. V., Volkova M. V., Buglova A. E., Rudenko E. V., Maslinskaya L. N., Petrovich D. M. et al. Clinical polymorphism of rheumatoid arthritis in the Belarusian patient population. Meditsina [Medicine], 2017, no. 2, pp. 63–70 (in Russian).Current and future trends in biomarker discovery and development of companion diagnostics for arthritis / D. S. Gibson [et al.] // Expert Rev. Mol. Diagn. – 2014. – Vol. 15, N 2. – P. 219–234. https://doi.org/10.1586/14737159.2015.969244Gibson D. S., Bustard M. J., McGeough C. M., Murray H. A., Crockard M. A., McDowell A., Blayney J. K., Gardiner P. V., Bjourson A. J. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Review of Molecular Diagnostics, 2014, vol. 15, no. 2, pp. 219–234. https://doi.org/10.1586/14737159.2015.969244Plant, D. Genetic and epigenetic predictors of responsiveness to treatment in RA / D. Plant, A. G. Wilson, A. Barton // Nat. Rev. Rheumatol. – 2014. – Vol. 10, N 6. – P. 329–337. https://doi.org/10.1038/nrrheum.2014.16Plant D., Wilson A. G., Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nature Reviews Rheumatology, 2014, vol. 10, no. 6, pp. 329–337. https://doi.org/10.1038/nrrheum.2014.16Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics / G. Dennis Jr. [et al.] // Arthritis Res. Ther. – 2014. – Vol. 16, N 2. – P. R90. https://doi.org/10.1186/ar4555Dennis Jr. G., Holweg C. T., Kummerfeld S. K., Choy D. F., Setiadi A., Hackney J. A. et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Research and Therapy, 2014, vol. 16, no. 2, pp. R90. https://doi.org/10.1186/ar4555Townsend, M. J. Molecular and cellular heterogeneity in the rheumatoid arthritis synovium: clinical correlates of synovitis / M. J. Townsend // Best Pract. Res. Clin. Rheumatol. – 2014. – Vol. 28, N 4. – P. 539–549. https://doi.org/10.1016/j.berh.2014.10.024Townsend M. J. Molecular and cellular heterogeneity in the Rheumatoid Arthritis synovium: clinical correlates of synovitis. Best Practice and Research Clinical Rheumatology, 2014, vol. 28, no. 4, pp. 539–549. https://doi.org/10.1016/j.berh.2014.10.024Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register / K. L. Hyrich [et al.] // Rheumatology. – 2006. – Vol. 45, N 12. – P. 1558–1565. https://doi.org/10.1093/rheumatology/kel149Hyrich K. L., Watson K. D., Silman A. J., Symmons D. P. M. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2006, vol. 45, no. 12, pp. 1558–1565. https://doi.org/10.1093/rheumatology/kel149Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA / J. L. Nam [et al.] // Ann. Rheumatic Dis. – 2010. – Vol. 69, N 6. – P. 976–986. https://doi.org/10.1136/ard.2009.126573Nam J. L., Winthrop K. L., van Vollenhoven R. F, Pavelka K., Valesini G., Hensor E. M. A. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases, 2010, vol. 69, no. 6, pp. 976–986. https://doi.org/10.1136/ard.2009.126573Daïen, C. I. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine / C. I. Daïen, J. Morel // Mediators Inflamm. – 2014. – Vol. 2014. – Art. ID 386148. https://doi.org/10.1155/2014/386148Daïen C. I., Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators of Inflammation, 2014, vol. 2014, art. ID 386148. https://doi.org/10.1155/2014/386148Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the CATCH observational study / S. M. Goodman [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 74, suppl. 2. – P. 138.2–139. https://doi.org/10.1136/annrheumdis-2015-eular.1973Goodman S. M., Ma Y., Zhang W., Schulman E., Bartlett S. J., Andersen K. M. et al. Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the CATCH observational study. Annals of the Rheumatic Diseases, 2015, vol. 74, suppl. 2, pp. 138.2–139. https://doi.org/10.1136/annrheumdis-2015-eular.1973Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine / E. Gremese [et al.] // Arthritis Care Res. – 2012. – Vol. 65, N 1. – P. 94–100. https://doi.org/ 10.1002/acr.21768Gremese E., Carletto A., Padovan M., Atzeni F., Raffeiner B., Giardina A. R. et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care and Research, 2012, vol. 65, no. 1, pp. 94–100. https://doi.org/10.1002/acr.21768Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts / S. Saevarsdottir [et al.] // Arthritis Rheum. – 2010. – Vol. 63, N 1. – P. 26–36. https://doi.org/10.1002/art.27758Saevarsdottir S., Wedrén S., Seddighzadeh M., Bengtsson C., Wesley A., Lindblad S., Askling J., Alfredsson L., Klareskog L. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis and Rheumatism, 2010, vol. 63, no. 1, pp. 26–36. https://doi.org/10.1002/art.27758Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register / L. E. Kristensen [et al.] // Rheumatology. – 2007. – Vol. 47, N 4. – P. 495–499. https://doi.org/10.1093/rheumatology/ken002Kristensen L. E., Kapetanovic M. C., Gülfe A., Soderlin M., Saxne T., Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology, 2007, vol. 47, no. 4, pp. 495–499. https://doi.org/10.1093/rheumatology/ken002Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British society for rheumatology biologics register / M. M. Soliman [et al.] // J. Rheumatol. – 2011. – Vol. 39, N 2. – P. 240–246. https://doi.org/10.3899/jrheum.110610Soliman M. M., Hyrich K. L., Lunt M., Watson K. D., Symmons D. P. M., Ashcroft D. M. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British society for rheumatology biologics register. Journal of Rheumatology, 2011, vol. 39, no. 2, pp. 240–246. https://doi.org/10.3899/jrheum.110610Van Schouwenburg, P. A. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis / P. A. van Schouwenburg, T. Rispens, G. J. Wolbink // Nat. Rev. Rheumatol. – 2013. – Vol. 9, N 3. – P. 164–172. https://doi.org/10.1038/nrrheum.2013.4Van Schouwenburg P. A., Rispens T., Wolbink G. J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nature Reviews Rheumatology, 2013, vol. 9, no. 3, pp. 164–172. https://doi.org/10.1038/nrrheum.2013.4Кундер, Е. В. Иммуногенность блокаторов фактора некроза опухоли альфа как причина резистентности к терапии / Е. В. Кундер // Лечеб. дело. – 2017. – № 2. – С. 55–64.Kunder E. V. Immunogenicity of tumor necrosis factor-alpha blockers as a cause of resistance to therapy. Lechebnoe delo [Therapeutics], 2017, no. 2, pp. 55–64 (in Russian).Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis / J. D. Isaacs [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 72, N 3. – P. 329–336. https://doi.org/10.1136/ annrheumdis-2011-201117Isaacs J. D., Cohen S. B., Emery P., Tak P., Wang J., Lei G., Williams S., Lal P., Read S. J. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Annals of the Rheumatic Diseases, 2012, vol. 72, no. 3, pp. 329–336. https://doi.org/10.1136/annrheumdis-2011-201117Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment / P. Lal [et al.] // Arthritis. Rheum. – 2011. – Vol. 63, N 12. – P. 3681–3691. https://doi.org/ 10.1002/art.30596Lal P., Su Z., Holweg C. T., Silverman G. J., Schwartzman S., Kelman A., Read S., Spaniolo G., Monroe J. G., Behrens T. W., Townsend M. J. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment Arthritis and Rheumatism, 2011, vol. 63, no. 12, pp. 3681–3691. https://doi.org/ 10.1002/art.30596Personalized medicine for rheumatoid arthritis:serological and clinical patients profiles to optimize B and T cell targeted therapy / E. Feist [et al.] // Z. Rheumatol. – 2013. – Vol. 72, N 1. – P. 49–58. https://doi.org/ 10.1007/s00393-011-0885-4Feist E., Dörner T. Personalized medicine for rheumatoid arthritis:serological and clinical patients profiles to optimize B and T cell targeted therapy. Zeitschrift für Rheumatologie, 2013, vol. 72, no. 1, pp. 49–58. https://doi.org/ 10.1007/s00393-011-0885-4Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis / J. Sellam [et al.] // Arthritis Res. Ther. – 2016. – Vol. 18, N 1. – Р. 294. https://doi.org/ 10.1186 / s13075-016-1190-zSellam J., Riviere E., Courties A., Rouzarie P.-O., Tolusso B., Vital E. M., Emery P., Ferraccioli G., Soubrier M., Ly B., Chavez H. H., Taoufic Y., Dougados M., Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Research and Therapy, 2016, vol. 18, no. 1, р. 294. https://doi.org/ 10.1186 / s13075-016-1190-zThe status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-tnfa agent treatment in patients with rheumatoid arthritis: a meta-analysis / Q. Lv [et al.] // Plos ONE. – 2014. – Vol. 9, N 2. – P. e89442. https://doi.org/10.1371/journal.pone.0089442Lv Q., Yin Y., Li X., Shan G., Wu X., Liang D., Li Y., Zhang X. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFa agent treatment in patients with rheumatoid arthritis: a metaanalysis. PLoS ONE, 2014, vol. 9, no. 2, p. e89442. https://doi.org/10.1371/journal.pone.0089442Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial / D. Porter [et al.] // Lancet. – 2016. – Vol. 388, N 10041. – P. 239–247. https://doi.org/10.1016/s0140-6736(16)00380-9Porter D., van Melckebeke J., Dale J., Messow C. M., McConnachie A., Walker A. et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet, 2016, vol. 388, no. 10041, pp. 239–247. https://doi.org/10.1016/s0140-6736(16)00380-9Singh, J. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review / J. A. Singh, S. Beg, M. A. Lopez-Olivo // J. Rheumatol. – 2011. – Vol. 38, N 1. – P. 10–20. https://doi.org/10.3899/jrheum.100717Singh J. A., Beg S., Lopez-Olivo M. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. Journal of Rheumatology, 2011, vol. 38, no. 1, pp. 10–20. https://doi.org/10.3899/jrheum.100717Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis / R. Alfonso-Cristancho [et al.] // Clin. Rheumatol. – 2016. – Vol. 36, N 1. – P. 25–34. https://doi.org/10.1007/ s10067-016-3435-2Alfonso-Cristancho R., Armstrong N., Arjunji R., Riemsma R., Worthy G., Ganguly R., Kleijnen J. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clinical Rheumatology, 2016, vol. 36, no. 1, pp. 25–34. https://doi.org/10.1007/s10067-016-3435-2Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial / C. Gabay [et al.] // Lancet. – 2013. – Vol. 381, N 9877. – P. 1541–1550. https://doi.org/10.1016/s0140-6736(13)60250-0Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet, 2013, vol. 381, no. 9877, pp. 1541–1550. https://doi.org/10.1016/s0140-6736(13)60250-0Alam, J. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy / J. Alam, I. Jantan, S. N. A. Bukhari // Biomed. Pharmacother. – 2017. – Vol. 92. – P. 615–633. https://doi.org/10.1016/j.biopha.2017.05.055Alam J., Jantan I., Bukhari S. N. A. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharma cotherapy. Biomedicine and Pharmacotherapy, 2017, vol. 92, pp. 615–633. https://doi.org/10.1016/j.biopha.2017.05.055Nishimoto, N. Interleukin 6: from bench to bedside / N. Nishimoto, T. Kishimoto // Nat. Clin. Pract. Rheumatol. – 2006. – Vol. 2, N 11. – P. 619–626. https://doi.org/10.1038/ncprheum0338Nishimoto N., Kishimoto T. Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology, 2006, vol. 2, no. 11, pp. 619–626. https://doi.org/10.1038/ncprheum0338Effectiveness of biologic and non biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data / S. K. Paul [et al.] // Semin. Arthr. Rheum. – 2018. – Vol. 47, N 4. – P. 478–484. https://doi.org/10.1016/j.semarthrit.2017.08.001Paul S. K., Montvida O., Best J. H., Gale S., Pethoe-Schramm A., Sarsour K. Effectiveness of biologic and non biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data. Seminars in Arthritis and Rheumatism, 2018, vol. 47, no. 4, pp. 478–484. https://doi.org/10.1016/j.semarthrit.2017.08.001Pandian, V. P. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies / V. P. Pandian, R. Srinivasan // Clin. Ophthalmol. – 2015. – Vol. 9. – P. 393–397. https://doi.org/10.2147/opth.s77210Pandian V. P., Srinivasan R. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies. Clinical Ophthalmology, 2015, vol. 9, pp. 393–397. https://doi.org/10.2147/opth.s77210Assmann, G. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers / G. Assmann, M. Pfreundschuh, J. Voswinkel // Clin. Exp. Rheumatol. – 2010. – Vol. 28, N 1, suppl. 57. – P. 81–83.Assmann G., Pfreundschuh M., Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clinical and Experimental Rheumatology, 2010, vol. 28, no. 1, suppl. 57, pp. 81–83.Chandra, P. A. Rituximab is useful in the treatment of Felty’s syndrome / P. A. Chandra, Y. Margulis, C. Schiff // Am. J. Ther. – 2008. – Vol. 15, N 4. – P. 321–322. https://doi.org/10.1097/mjt.0b013e318164bf32Chandra P. A., Margulis Y., Schiff C. Rituximab is useful in the treatment of Felty’s syndrome. American Journal of Therapeutics, 2008, vol. 15, no. 4, pp. 321–322. https://doi.org/10.1097/mjt.0b013e318164bf32Iaccheri, B. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis / B. Iaccheri [et al.] // Ocul. Immunol. Infamm. – 2010. – Vol. 18, N 3. – P. 223–225. https://doi.org/10.3109/09273941003739928Iaccheri B., Androudi S., Bocci E. B., Gerli R., Cagini C., Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocular Immunology and Inflammation, 2010, vol. 18, no. 3, pp. 223–225. https://doi.org/10.3109/09273941003739928Coexistence of rheumatoid arthritis and ankylosing spondylitis / T. A. Barczyńska [et al.] // Reumatologia. – 2015. – Vol. 5. – P. 279–285. https://doi.org/10.5114/reum.2015.55832Barczyńska T. A., Węgierska M., Żuchowski P., Dura M., Zalewska J., Waszczak M., Jeka S. Coexistence of rheumatoid arthritis and ankylosing spondylitis. Reumatologia, 2015, vol. 5, pp. 279–285. https://doi.org/10.5114/reum.2015.55832Double disease in rheumatology: coexistence of rheumatoid arthritis and psoriatic arthritis / R. Mazzucchelli [et al.] // Clin. Exp. Rheumatol. – 1992. – Vol. 10 (1). – P. 83–85.Mazzucchelli R., Yebra M., Barbadillo C., Berrocal E., Gea J. C., Andreu-Sanchez J. L. Double disease in rheumatology: coexistence of rheumatoid arthritis and psoriatic arthritis. Clinical and Experimental Rheumatology, 1992, vol. 10, no. 1, pp. 83–85.Toussirot, E. Crohn’s disease associated with seropositive rheumatoid arthritis / E. Toussirot, D. Wendling // Clin. Exp. Rheumatol. – 1997. – Vol. 15, N 3. – P. 307–311.Toussirot E., Wendling D. Crohn’s disease associated with seropositive rheumatoid arthritis. Clinical and Experimental Rheumatology, 1997, vol. 15, no. 3, pp. 307–311.Bogas, M. Erosive enteropathy in a patient with polyarthritis / M. Bogas, M. C. Afonso, D. Araújo // Acta Reumatol. Port. – 2006. – Vol. 31, N 4. – P. 349–354.Bogas M., Afonso M. C., Araújo D. Erosive enteropathy in a patient with polyarthritis. Acta Reumatologica Portuguesa, 2006, vol. 31, no. 4, pp. 349–354.Ulcerative colitis and rheumatoid arthritis: a rare association--case report / V. A. Cruz [et al.] // Rev. Bras. Reumatol. – 2012. – Vol. 52, N 4. – P. 648–650.Cruz V. A., Yamaguchi L., Ribeiro C. N., Magalhães Vde O., Rego J., Silva N. A. Ulcerative colitis and rheumatoid arthritis: a rare association – case report. Revista Brasileira de Reumatologia, 2012, vol. 52, no. 4, pp. 648–650.Azevedo, V. F. Concurrent rheumatoid arthritis and ankylosing spondylitis in one patient: the importance of new classification criteria / V. F. Azevedo, P. G. Buiar // Rev. Bras. Reumatol. (En. ed.). – 2013. – Vol. 53, N 1. – P. 111–119. https://doi.org/10.1016/s2255-5021(13)70011-7Azevedo V. F., Buiar P. G. Concurrent rheumatoid arthritis and ankylosing spondylitis in one patient: the importance of new classification criteria. Revista Brasileira de Reumatologia (English Edition), 2013, vol. 53, no. 1, pp. 111–119. https://doi.org/10.1016/s2255-5021(13)70011-7Association of HLA alleles and clinical features in patients with synovitis of recent onset / H. S. El-Gabalawy [et al.] // Arthritis Rheum. – 1999. – Vol. 42, N 8. – P. 1696–1705. https://doi.org/10.1002/1529-0131(199908)42:83.0.co;2-kEl-Gabalawy H. S., Goldbabach-Mansky R., Smith D., Arayssi T., Bale S., Gulko P. et al. Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis and Rheumatism, 1999, 42, no. 8, pp. 1696–1705. https://doi.org/10.1002/1529-0131(199908)42:83.0.co;2-kJajić, Z. HLA B27 antigen and rheumatoid arthritis / Z. Jajić, I. Jajić // Acta Med. Iugosl. – 1991. – Vol. 45, N 3. – P. 195–202.Jajić Z., Jajić I. HLA B27 antigen and rheumatoid arthritis. Acta Medica Iugoslavica, 1991, vol. 45, no. 3, pp. 195–202. 44. Mera-Varela A., Ferreiro-Iglesias A., Perez-Pampin E., Porto-Silva M., Gómez-Reino J. J., Gonzalez A. Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study. PLoS ONE, 2013, vol. 8, no. 3, p. e58616. https://doi.org/10.1371/journal.pone.0058616Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study / A. Mera-Varela [et al.] // PLoS ONE. – 2013. – Vol. 8, N 3. – P. e58616. https://doi.org/10.1371/journal.pone.0058616Saraux A., Guedes C., Allain J., Vails I., Baron D., Youinou P., Le Goff P. HLA-B27 in French patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 1997, vol. 26, no. 4, pp. 269–271. https://doi.org/10.3109/03009749709105315HLA-B27 in French patients with rheumatoid arthritis / A. Saraux [et al.] // Scand. J. Rheumatol. – 1997. – Vol. 26, N 4. – P. 269–271. https://doi.org/10.3109/03009749709105315Jurik A. G., de Carvalho A., Graudal H. Radiographic visualisation of seropositive rheumatoid arthritis in carriers of HLA-B27. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 1987, vol. 147, no. 7, pp. 14–20. https://doi.org/10.1055/s-2008-1048582Jurik, A. G. Radiographic visualisation of seropositive rheumatoid arthritis in carriers of HLA-B27 / A. G. Jurik, A. de Carvalho, H. Graudal // RöFo – Fortschritte auf dem Gebiet der R. – 1987. – Vol. 147, N 7. – P. 14–20. https://doi.org/10.1055/s-2008-1048582Jurik, A. G. Radiographic visualisation of seropositive rheumatoid arthritis in carriers of HLA-B27 / A. G. Jurik, A. de Carvalho, H. Graudal // RöFo – Fortschritte auf dem Gebiet der R. – 1987. – Vol. 147, N 7. – P. 14–20. https://doi.org/10.1055/s-2008-1048582

The authors declare that there are no conflicts of interest present.